Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Oct 14;24(1):309.
doi: 10.1186/s12893-024-02554-5.

The impact of an open-label design on human amniotic membranes vs. silver sulfadiazine dressings for second-degree burns: a randomized controlled clinical trial

Mohammad Hossein Moghimi  1 , Mehran Salehian  2 , Mohammad Abdi  3 , Mehran Tahrekhani  4 , Alireza Safaei  5 , Koorosh Kamali  6
Affiliations
Randomized Controlled Trial

The impact of an open-label design on human amniotic membranes vs. silver sulfadiazine dressings for second-degree burns: a randomized controlled clinical trial

Mohammad Hossein Moghimi et al. BMC Surg. .

Abstract

Background: Burn wounds require optimal medical management due to associated psycho-emotional and socioeconomic impacts and severe pain. The use of synthetic and biological dressings improves healing and reduces burn wound complications. The present study aimed to compare the outcomes of using human amniotic membrane (hAM) dressings and conventional silver sulfadiazine (SSDZ) ointment dressings in the management of second-degree burn wounds.

Methods: Fifty patients who participated in this clinical trial were divided into two groups via simple randomization. All the enrolled patients, who had burnt in the last 24 h, had thermal damage mechanisms and were suffering from less than 20% second-degree heat-burn wounds on the skin surface. The target group (n = 25) was treated with hAM, and the control group (n = 25) was treated with SSDZ ointment. The researcher-designed checklist was used to determine the clinical performance in the follow-up assessments on days 7, 14, and 30.

Results: No significant differences were detected in terms of sex, age, or percentage of burn wounds (p > 0.05). Wound epithelialization at days 7, 14, and 30, scar formation, wound pigmentation, pain severity, analgesia requirements, and hospital stay length (on day 30) were significantly lower in the target group (treated with hAM) than in the control group (treated with SSDZ ointment) (p < 0.05). However, treatment costs in the target group ($170) were significantly higher than those in the control group ($71) (p < 0.001).

Conclusion: Despite its higher cost, hAM, as a technology-based therapy dressing, demonstrates superiority over SSDZ ointment in terms of wound healing and pain management.

Keywords: Amniotic membrane; Burns; Clinical trial; Silver sulfadiazine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Inclusion and exclusion criteria. The diagram depicts the algorithm in which the participants were included and/or excluded from the study
Fig. 2
Fig. 2
Epithelialization presence in hAM and SSDZ groups. Wound healing was significantly quicker in hAM group compared to SSDZ counterparts (p < 0.001)
Fig. 3
Fig. 3
Scar of wound in hAM and SSDZ groups. Patients who had hAM dressing reported did not have severe scar of wound as opposed to SSDZ cohorts (p < 0.001)
Fig. 4
Fig. 4
Average pain score in the hAM and SSDZ groups. Patients who had hAM dressings reported significantly lower pain scores than SSDZ patients did (p < 0.001)
Fig. 5
Fig. 5
Average hospital stays for hAM and SSDZ groups
Fig. 6
Fig. 6
Mean of pethidine consumption in hAM and SSDZ groups. Administration of pethidine in hAM dressing group was significantly lower than SSDZ cohorts (p < 0.001)
Fig. 7
Fig. 7
Average treatment expenditure for HAM vs. SSDZ. Treatment utilizing HAM dressing was significantly more expensive than SSDZ (p < 0.001)
Fig. 8
Fig. 8
The patients’ wound who have been treated with human amniotic membrane and silver sulfadiazine. (A) Second-degree burn wound on the edge of the right foot on the first day have been treated with human amniotic membrane. (B) Second-degree burn wound on the edge of the right foot on day 7 have been treated with human amniotic membrane. The amniotic membrane gradually peels off the skin as the wound heals, leaving a smooth and scarless surface. (C) Second-degree burn wound on the edge of the right foot on day 30 have been treated with human amniotic membrane
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Opriessnig E, Luze H, Smolle C, Draschl A, Zrim R, Giretzlehner M, Kamolz L-P, Nischwitz SP. Epidemiology of burn injury and the ideal dressing in global burn care – Regional differences explored. Burns. 2023;49(1):1–14. - PubMed
    1. Odondi RN, Shitsinzi R, Emarah A. Clinical patterns and early outcomes of burn injuries in patients admitted at the Moi Teaching and Referral Hospital in Eldoret, Western Kenya. Heliyon. 2020;6(3):e03629. - PMC - PubMed
    1. WHO. Burns-WHO | World Health Organization. 2018.
    1. Abraham JP, Plourde BD, Vallez LJ, Nelson-Cheeseman BB, Stark JR, Sparrow EM, Gorman JM. Skin burns. Theory Appl Heat Trans Hum. 2018;2:723–39.
    1. Resch A, Staud C, Radtke C. Nanocellulose-based wound dressing for conservative wound management in children with second‐degree burns. Int Wound J. 2021;18(4):478–86. - PMC - PubMed

Publication types

LinkOut - more resources